- Home
- AIO vs VIR Comparison
AIO vs VIR Comparison
Compare AIO & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIO
- VIR
- Stock Information
- Founded
- AIO 2019
- VIR 2016
- Country
- AIO United States
- VIR United States
- Employees
- AIO N/A
- VIR N/A
- Industry
- AIO Finance/Investors Services
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- AIO Finance
- VIR Health Care
- Exchange
- AIO Nasdaq
- VIR Nasdaq
- Market Cap
- AIO 808.3M
- VIR 706.4M
- IPO Year
- AIO N/A
- VIR 2019
- Fundamental
- Price
- AIO $24.30
- VIR $5.65
- Analyst Decision
- AIO
- VIR Strong Buy
- Analyst Count
- AIO 0
- VIR 8
- Target Price
- AIO N/A
- VIR $30.25
- AVG Volume (30 Days)
- AIO 141.5K
- VIR 1.2M
- Earning Date
- AIO 01-01-0001
- VIR 07-31-2025
- Dividend Yield
- AIO 9.05%
- VIR N/A
- EPS Growth
- AIO N/A
- VIR N/A
- EPS
- AIO N/A
- VIR N/A
- Revenue
- AIO N/A
- VIR $20,861,000.00
- Revenue This Year
- AIO N/A
- VIR N/A
- Revenue Next Year
- AIO N/A
- VIR $0.62
- P/E Ratio
- AIO N/A
- VIR N/A
- Revenue Growth
- AIO N/A
- VIR N/A
- 52 Week Low
- AIO $15.09
- VIR $4.32
- 52 Week High
- AIO $20.25
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- AIO 55.54
- VIR 57.21
- Support Level
- AIO $24.38
- VIR $5.20
- Resistance Level
- AIO $24.78
- VIR $6.23
- Average True Range (ATR)
- AIO 0.33
- VIR 0.30
- MACD
- AIO -0.08
- VIR 0.07
- Stochastic Oscillator
- AIO 61.40
- VIR 56.06
About AIO Virtus Artificial Intelligence & Technology Opportunities Fund of Beneficial Interest
Virtus Artificial Intelligence & Technology Opportunities Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.